Multiple Myeloma is a form of blood cancer. Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced. In myeloma, unusually large numbers of abnormal plasma cells gather in bone marrow and stop it from producing an important part of your immune system. Multiple myeloma is a cancer formed by malignant plasma cells. Multiple myeloma is characterized with low blood counts, bone and calcium problems, infections, kidney problems and nervous system symptoms. Usually the age factor is considered as the most prominent factor in multiple myeloma cases.
Multiple myeloma was considered to be a non-treatable disease but hopes have arrived with the approval of Darzalex which was a much awaited product and has shown positive results in the trials. Many other products are in the pipeline and will arrive after some time. Darzalex is an antibody with immense potential and was the first monoclonal antibody approved by the FDA for the treatment of heavily pretreated retreated multiple myeloma. More experiments have started to check out Darzalex in combinations to find out its effectiveness in case of other problems too.
Request a sample of this report at http://www.orbisresearch.com/contacts/request-sample/101996 .
The key factors which are anticipated to drive multiple myeloma market include increased penetration of cancer drugs, increase in ageing population, rising obese population and increase in healthcare expenditure. Some of the significant developments of this industry include upcoming new innovative products in the market, trend of combination therapies, and chance of new players. However, the challenge to be faced ahead is high price and legal regulations.
This report offers a comprehensive analysis of the Global Multiple Myeloma market . Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global market is reined by few major players namely Johnson & Johnson, Roche Holding, Sanofi and Novartis. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
Table of Contents from the report are as below:
1. Blood Cancer: An Introduction
2. Multiple Myeloma
3. Multiple Myeloma Market Analysis
4. Regional Markets
5. Market Dynamics
6. Competitive Landscape
7. Key Product Analysis
8. Company Profiles
List Of Tables:
Types of Blood Cancer
Global Blood Cancer Market Forecast by Value (2015/2020)
Global Multiple Myeloma Market Forecast by Value (2016-2030)
Global Forefront Treated Patients Forecast (2016-2030)
Global Reverted Treated Patients Forecast (2016-2030)
The US Multiple Myeloma Market Forecast by Value (2016-2030)
The US Forefront Treated Patients Forecast (2016-2030)
The US Reverted Treated Patients Forecast (2016-2030)
Europe Multiple Myeloma Market Forecast by Value (2016-2030)
Europe Forefront Treated Patients Forecast (2016-2030)
Europe Reverted Treated Patients Forecast (2016-2030)
ROW Multiple Myeloma Market Forecast by Value (2016-2030)
ROW Forefront Treated Patients Forecast (2016-2030)
ROW Reverted Treated Patients Forecast (2016-2030)
Global Ageing Population (2006-2015)
Global Obese Population (2007-2015)
Global Healthcare Expenditure (2007-2015)
Darzalex Global Sales Forecast by Value (2016-2020)
The US Darzalex Forefront Market Penetration Forecast (2016-2030)
The US Reverted Patients Market Penetration Forecast (2016-2030)
Europe Darzalex Forefront Market Penetration Forecast (2016-2030)
Europe Reverted Patients Market Penetration Forecast (2016-2030)
ROW Darzalex Forefront Market Penetration Forecast (2016-2030)
ROW Reverted Patients Market Penetration Forecast (2016-2030)
Johnson & Johnson Sales by Segment (2015)
Johnson & Johnson Net Sales and Net Income (2011-2015)
Roche’s Revenue Share by Segment (2015)
Roche’s Revenue and Net Income (2011-2015)
Sanofi’s Revenue Share by Segment (2015)
Sanofi’s Revenue Share by Geography (2015)
Sanofi’s Revenue and Net Income (2011-2015)
Novartis’ Revenue Share by Business Segments (2015)
Novartis’ Revenue Share by Geography (2015)
Novartis’ Net Sales and Net Income (2011-2015)
List of Tables
Types of Monoclonal Antibodies
Multiple Myeloma Therapies with Mechanism by Product
Phase I/II Comparative Response Data in Darzalex and Isatuximab
Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/101996 .
Browse more reports on Pharmaceuticals and Healthcare Market at http://www.orbisresearch.com/market-reports/pharmaceuticals-and-healthcare.html .
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Company Name: Orbis Research
Contact Person: Hector Costello
Phone: +1 (214) 884-6817
Address:4144N Central Expressway, Suite 600
Country: United States